China Biotech Services cites HK$29.01 million net liabilities as it clarifies rationale for PHC, Premier Medicare disposal

• China Biotech Services issued supplemental rationale for its planned disposal of PHC Medical Diagnostic Centre and Premier Medicare Services.
• As of March 31, 2026, the targets had unaudited net liabilities of HK$29.01 million, largely tied to intercompany advances.
• The Hong Kong lab testing unit faced intense competition and high costs, driving cash-flow strain and ongoing losses.
• Proceeds and focus shift toward the cancer treatment segment, centered on boron neutron capture therapy and a trial-stage Pengbo (Hainan) Boron Neutron Hospital.
• An MOU with Stella Pharma targets China regulatory approval for Steboronine, with expected exclusive China manufacturing and sales rights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Biotech Services Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260602-12182979), on June 02, 2026, and is solely responsible for the information contained therein.